Industry News

Boston Scientific Corporation will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2016 on Wednesday, October 26, 2016 at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. A live webcast of the conference call will be available on the Investor..."/>
Boston Scientific to Webcast Conference Call Discussing Third Quarter 2016 Financial Results on October 26
VIVUS, Inc. and Metuchen Pharmaceuticals LLC today announced an agreement providing Metuchen a fully-paid, perpetual license for exclusive rights to commercialize STENDRA ® in the U.S., Canada, South America and India. The parties simultaneously signed a commercial supply agreement pursuant to which VIVUS will be responsible for the manufacture and supply of STENDRA to Metuchen for a mutually agreed term. For a period of 180 days,..."/>
VIVUS and Metuchen Pharmaceuticals Announce License Agreement for Commercial Rights to STENDRA
Jazz Pharmaceuticals plc today announced the initiation of a rolling submission of a New Drug Application to the United States Food and Drug Administration on September 30, 2016, seeking marketing approval of Vyxeos™, an investigational agent for the treatment of acute myeloid leukemia. The company expects to complete the submission of the NDA by early 2017, and will request a priority review. "Our initiation of the rolling NDA submission for..."/>
Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission by Early 2017
Hemostemix Inc., a clinical-stage autologous cell-therapy company, announces that two new patents have been granted in 2016 in the United States and Canada. Patent and Trademark Office granted patent US 9,404,084 titled "Regulating Stem Cells". Itis the fourth Hemostemix patent issued in the United States."/>
Hemostemix Granted Two Additional Patents in the US and in Canada
Thermo Fisher Scientific, the world leader in serving science, today announced the expansion of its Fisher BioServices cryogenic service capabilities in Japan."/>
Thermo Fisher Scientific Expands Global Footprint to Support Cell and Gene Therapy Clinical Trials in Japan
CareDx, Inc., a molecular diagnostics company, today called for a reversal of a decision by the Centers for Medicare& Medicaid Services to drastically reduce reimbursement for its diagnostic test AlloMap– the only FDA-cleared blood test to monitor heart transplant patients for rejection, and the only alternative to more costly and invasive biopsies. "This decision is unwise, unfair, and misaligned with President Obama's Precision Medicine..."/>
CMS Proposal Threatens Availability Of Standard Of Care Blood Test To Heart Transplant Patients
Arena Pharmaceuticals, Inc. today announced the availability of BELVIQ XR ® CIV extended-release 20 mg tablets, a new once-daily dosing option that may help some patients achieve and maintain weight loss. "With more than 78 million adults who are obese in this country and obesity rates on the rise, there is an increased need for additional therapeutic options to help patients better manage their weight," said..."/>
Eisai Inc. and Arena Pharmaceuticals Announce Availability of Once-Daily BELVIQ XR® (lorcaserin HCl) Extended-Release Tablets
Spectral Medical Inc. a Phase III company developing the first treatment for patients with endotoxemic septic shock using a medical device, today announced the top line results of its Phase III pivotal trial which enrolled a total of 450 patients, including a pre specified population of 243 patients with a high multiple organ dysfunction score either treated with two Toraymyxin™ columns or given two shams. While the trial did not, with this sample size,..."/>
Spectral Announces Clinical Trial Results
Five Star Quality Care, Inc. at a price of $3.00 per share. The offer price represents a 57% premium over FVE’ s closing price of $1.91 per share on September 30, 2016, the last trading day prior to today's announcement, and represents a 34% premium over the average year to date closing trading prices of FVE shares of $2.24 per share."/>
ABP Acquisition LLC Announces Intention to Commence Tender Offer for up to 10,000,000 Shares of Common Stock of Five Star Quality Care, Inc.
AmerisourceBergen Corporation today announced that it plans to release its results for the Fourth Quarter Fiscal 2016 on Wednesday, November 2, 2016 prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 11:00 a.m. Eastern Time on November 2, 2016.. Participating in the conference call will be:."/>
AmerisourceBergen Announces Date and Time for Fourth Quarter Fiscal 2016 Earnings Release
Lion Biotechnologies, Inc., a biotechnology company developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes, today announced the appointment of Gregory T. Schiffman, MBA as Chief Financial Officer of the company, effective immediately. "As we continue to build the management team into a fully integrated oncology organization, we are delighted to welcome Greg to the team," said Lion Biotechnologies President and CEO, Maria Fardis,..."/>
Lion Biotechnologies Appoints Gregory Schiffman as Chief Financial Officer
NxStage Medical, Inc., a leading medical technology company focused on advancing renal care, today announced a three-year agreement with Satellite Healthcare that includes NxStage's innovative Nx2me Connected Health ® platform for their patients performing home hemodialysis therapy with the NxStage ® System One™. Satellite Healthcare is a national not-for-profit and the sixth largest provider of patient-centered dialysis and..."/>
NxStage and Satellite Healthcare Announce New Three-Year Home Hemodialysis Agreement that Includes Innovative Nx2me Platform
Five Star Quality Care, Inc., acting by a special committee, granted ABP Acquisition LLC a conditional exemption from certain Five Star bylaw and charter restrictions applicable to certain ownership limitations of not more than 5% and 9.8% of Five Star’ s shares of common stock, respectively. Five Star understands that ABP Acquisition LLC intends to make a tender offer for up to 10,000,000 shares at $3.00 per share."/>
Five Star Quality Care, Inc. Grants Certain Ownership Limitation Exemptions to ABP Acquisition LLC
Acacia Diversified Holdings, Inc. today announced that its wholly-owned subsidiary, MariJ Pharmaceuticals, Inc., has received an Organic Certification for its proprietary CO2 mobile cannabis oil extraction process and handling. OneCert, Inc. issued MariJ an Organic Certification under the U.S National Organic Program effective September 28, 2016."/>
Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, today announced a partnership with the Hepatitis B Foundation to support the Patient Storytelling Campaign. This campaign is organized to raise awareness about chronic HBV infection, a global medical unmet need, decrease the associated stigma and discrimination, and promote the importance of increased testing..."/>
Arbutus Recognizes Liver Cancer Awareness Month with Grant to Support the Hepatitis B Foundation’s Patient Storytelling Campaign
Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that preliminary data from an ongoing open-label Phase 2 study of XmAb ® 5871 in patients with IgG4-Related Disease will be presented during an oral presentation on Sunday, November 13 at the American College of Rheumatology 2016..."/>
Preliminary Data from the Ongoing Open-Label XmAb5871 Phase 2 Pilot Study in IgG4-Related Disease to be presented at American College of Rheumatology (ACR) 2016 Annual Meeting
Merus Labs International Inc. is pleased to announce that it has made the second of its regularly scheduled quarterly principal repayments under its new credit facility and achieved a 0.5% reduction in the annual interest rate under the credit facility. On September 30, 2016, Merus made a second payment on its term debt of approximately $8 million. Merus is required to make quarterly principal payments under this Euro-denominated facility,..."/>
Merus Labs Announces Reduced Interest Rate on Senior Secured Debt and Reduced Leverage
Merus Labs International Inc. is pleased to announce that it has made the second of its regularly scheduled quarterly principal repayments under its new credit facility and achieved a 0.5% reduction in the annual interest rate under the credit facility. On September 30, 2016, Merus made a second payment on its term debt of approximately $8 million. Merus is required to make quarterly principal payments under this Euro-denominated facility, which will..."/>
Merus Labs Announces Reduced Interest Rate on Senior Secured Debt and Reduced Leverage
K2M Group Holdings, Inc., a global medical device company focused on designing, developing and commercializing innovative and proprietary complex spine and minimally invasive spine technologies and techniques, today announced third quarter 2016 financial results will be released after the market close on November 2nd.. Management will host a conference call at 5:00 p.m. Eastern Time on November 2nd to discuss the results of the quarter, and to host a..."/>
K2M Group Holdings, Inc. to Release Third Quarter 2016 Financial Results on November 2nd
Editas Medicine, Inc., a leading genome editing company, announced today the appointment of Gerald Cox, M.D., Ph.D., as Chief Medical Officer."/>
Editas Medicine Expands Senior Management Team
INC Research Holdings, Inc., a leading, global Phase I to IV contract research organization, today announced the promotions of Michael Gibertini, PhD, and Tara Fitzgerald to key executive leadership roles within the Company. Gibertini, who currently serves as INC Research’ s President, Clinical Development, has been promoted to Chief Operating Officer succeeding Alistair Macdonald while Tara Fitzgerald, Executive Vice President, Biometrics, has been..."/>
INC Research Announces Executive Leadership Promotions
TRACON Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age? related macular degeneration and fibrotic diseases, today announced the successful completion of an End-of-Phase 2 meeting with the United States..."/>
TRACON Pharmaceuticals Announces Successful Meetings with FDA and EMA for TRC105 (carotuximab) in Angiosarcoma

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology797 Articles
Consumer Discretionary705 Articles
Financials691 Articles
Industrials541 Articles
Health Care516 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at